Prognostic value of NT-proBNP in patients with severe COVID-19

Prognostic value of NT-proBNP in patients with severe COVID-19

Lei Gao, Dan Jiang, Xuesong Wen, Xiao-cheng Cheng, Min SUN, Bin He, Lin-na You, Peng Lei, Xiao Wei Tan, Shu Qin, Guoqiang Cai, Dongying Zhang

Abstract Background The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown. Methods The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records. Results The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death. Conclusion NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19. Trial registration ClinicalTrials, NCT04292964. Registered 03 March 2020,

2020

NT-proBNT, COVID-19, SARS-CoV-2, outcome

DOI: 10.1186/s12931-020-01352-w

Respiratory Research

BMC

Diseases of the respiratory system

EN